UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 53

Sortiert nach

Assays for predicting and monitoring responses to lung cancer immunotherapy

Cancer biology & medicine, 2015-06, Vol.12 (2), p.87-95

Cristina Teixido Niki Karachaliou Maria Gonzalez-Cao Daniela Morales-Espinosa Rafael Rosell

2015

Link zum Volltext

Verfügbarkeit prüfen

Understanding the function and dysfunction of the immune system in lung cancer： the role of immune checkpoints

Cancer biology & medicine, 2015-06, Vol.12 (2), p.79-86

2015

Link zum Volltext

Verfügbarkeit prüfen

Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients

British journal of cancer, 2017-02, Vol.116 (6), p.802-810

2017

Link zum Volltext

Verfügbarkeit prüfen

The progressive elevation of alpha fetoprotein for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis

BMC cancer, 2007-02, Vol.7 (1), p.28-28, Article 28

2007

Link zum Volltext

Verfügbarkeit prüfen

Prolonged Exposure to Lead Lowers the Threshold of Pentylenetetrazole‐induced Seizures in Rats

Epilepsia (Copenhagen), 2005-10, Vol.46 (10), p.1599-1602

2005

Link zum Volltext

Verfügbarkeit prüfen

Erratum to Assays for predicting and monitoring responses to lung cancer immunotherapy

Cancer biology & medicine, 2015-09, Vol.12 (3), p.259-259

2015

Link zum Volltext

Verfügbarkeit prüfen

Colchicine delays the development of hepatocellular carcinoma in patients with hepatitis virus‐related liver cirrhosis

Cancer, 2006-10, Vol.107 (8), p.1852-1858

2006

Link zum Volltext

Verfügbarkeit prüfen

Targeting PD-1/PD-L1 in lung cancer: current perspectives

Lung cancer (Auckland), 2015-01, Vol.6 (default), p.55-70

2015

Link zum Volltext

Verfügbarkeit prüfen

Tackling hurdles in front of young clinical investigators in oncology – Results from an international survey

European journal of surgical oncology, 2024-06, Vol.50 (6), p.108031-108031, Article 108031

2024

Link zum Volltext

Verfügbarkeit prüfen

Treatment for small cell lung cancer, where are we now?—a review

Translational lung cancer research, 2016-02, Vol.5 (1), p.26-38

2016

Link zum Volltext

Verfügbarkeit prüfen

AFM24 in combination with atezolizumab in patients with advanced EGFR-expressing solid tumors: Phase 1/2a study design and rationale

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS2673-TPS2673

2022

Link zum Volltext

Verfügbarkeit prüfen

Response of negative estrogen-receptor hepatocarcinoma to tamoxifen, and survival of non-resectable patients

Annals of hepatology, 2006-10, Vol.5 (4), p.263-267

2006

Link zum Volltext

Verfügbarkeit prüfen

A phase 1/2a open label, multicenter study to assess the safety, tolerability, pharmacokinetics, and efficacy of AFM24 in patients with advanced solid cancers: Study design and rationale

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS2672-TPS2672

2022

Link zum Volltext

Verfügbarkeit prüfen

Preface on small cell lung cancer

Translational lung cancer research, 2016-02, Vol.5 (1), p.1-1

2016

Link zum Volltext

Verfügbarkeit prüfen

Second-line treatment in EGFR-unselected patients: is it time to close one arm of this river's DELTA?

Journal of thoracic disease, 2015-03, Vol.7 (3), p.227-229

2015

Link zum Volltext

Verfügbarkeit prüfen

Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond

Expert review of anticancer therapy, 2014-07, Vol.14 (7), p.807-815

2014

Link zum Volltext

Verfügbarkeit prüfen

Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer

Scientific reports, 2023-03, Vol.13 (1), p.3620-3620, Article 3620

2023

Link zum Volltext

Verfügbarkeit prüfen

BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer

Scientific reports, 2015-12, Vol.5 (1), p.17499, Article 17499

2015

Link zum Volltext

Verfügbarkeit prüfen

Pharmacogenomics in the treatment of lung cancer: an update

Pharmacogenomics, 2015-10, Vol.16 (15), p.1751-1760

2015

Link zum Volltext

Verfügbarkeit prüfen

Neuroendocrine tumors of uterine cervix in Mexican women

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e15569-e15569

2012

Link zum Volltext

Verfügbarkeit prüfen

CHK 1 inhibition as a therapeutic approach in KRAS mutated and squamous cell carcinoma NSCLC patients

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.11581-11581

2016

Link zum Volltext

Verfügbarkeit prüfen

Fusion gene and splice variant analyses in liquid biopsies of lung cancer patients

Translational lung cancer research, 2016-10, Vol.5 (5), p.525-531

2016

Link zum Volltext

Verfügbarkeit prüfen

746 AFM24 and atezolizumab combination in patients with advanced epidermal growth factor receptor-expressing (EGFR+) solid tumors: Initial results from the phase 1 dose-escalation study

Journal for immunotherapy of cancer, 2022, Vol.10 (Suppl 2), p.A779-A779

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 53

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(42)
Mit Volltextzugriff
(52)

Publikationsform

Sprache

Englisch
(53)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Assays for predicting and monitoring responses to lung cancer immunotherapy

Understanding the function and dysfunction of the immune system in lung cancer： the role of immune checkpoints

Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients

ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability

The progressive elevation of alpha fetoprotein for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis

Prolonged Exposure to Lead Lowers the Threshold of Pentylenetetrazole‐induced Seizures in Rats

Erratum to Assays for predicting and monitoring responses to lung cancer immunotherapy

Colchicine delays the development of hepatocellular carcinoma in patients with hepatitis virus‐related liver cirrhosis

Targeting PD-1/PD-L1 in lung cancer: current perspectives

Tackling hurdles in front of young clinical investigators in oncology – Results from an international survey

Treatment for small cell lung cancer, where are we now?—a review

AFM24 in combination with atezolizumab in patients with advanced EGFR-expressing solid tumors: Phase 1/2a study design and rationale

Response of negative estrogen-receptor hepatocarcinoma to tamoxifen, and survival of non-resectable patients

A phase 1/2a open label, multicenter study to assess the safety, tolerability, pharmacokinetics, and efficacy of AFM24 in patients with advanced solid cancers: Study design and rationale

Preface on small cell lung cancer

Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial

Second-line treatment in EGFR-unselected patients: is it time to close one arm of this river's DELTA?

Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond

Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer

BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer

Pharmacogenomics in the treatment of lung cancer: an update

Neuroendocrine tumors of uterine cervix in Mexican women

CHK 1 inhibition as a therapeutic approach in KRAS mutated and squamous cell carcinoma NSCLC patients

Fusion gene and splice variant analyses in liquid biopsies of lung cancer patients

746 AFM24 and atezolizumab combination in patients with advanced epidermal growth factor receptor-expressing (EGFR+) solid tumors: Initial results from the phase 1 dose-escalation study

Suchergebnisse filtern